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OrganellesIntegration of genetic and metabolic network holds promise for providing insight into human disease. Coro-
nary artery disease (CAD) is strongly heritable, but the heritability of metabolic compounds has not been
evaluated in human metabolic context. Here we performed a genetic-based computational approach within
eight sub-cellular networks from Edinburgh Human Metabolic Network to identify signiﬁcant genetic risk
compounds (SGRCs) of CAD. Our results provide the evidence that the high heritabilities of SGRCs played
an important role in CAD pathogenesis. Besides, SGRCs were discovered to be strongly associated with
lipid metabolism. We also established a possible disease-causing reference table to decipher genetic associa-
tions of SGRCs with CAD. Comparing with traditional method, RCM experienced better performance in CAD
genetic risk compounds' identiﬁcation. These ﬁndings provided novel insights into CAD pathogenesis from
a genetic perspective.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Coronary artery disease (CAD) is rapidly becoming the leading
cause of death in the world, and is considered to be closely relevant
with genetics and biological metabolism [1]. Current studies on CAD
are basically relying on detecting the variation of CAD related meta-
bolic bio-markers and identifying their functions for clinical diagnosis
and treatment [2]. Understanding the role of metabolic compounds
and their interaction with environmental factors in CAD is the key
to the development of safe and efﬁcient therapies, to diagnosis and
to prevention [3].
The genetic predilection of CAD is well established. For example,
family history has been proved to be one of the independent risk factors
for CAD [4]. Many metabolic risk factors for CAD need further explora-
tions. Genome-wide association studies (GWAS) have great power in
CAD genetic risk researches [5–8]. Chen and Zhang [9] utilized human
metabolic pathways and high-throughput SNP datasets to ﬁnd genetic
risk factors which are related with complex diseases. Suhre and Shin
[3] used a GWAS with non-targeted metabolites to identify genetic
loci associated metabolites. In both studies, the majority of the analytes
related with CAD genetics remained unidentiﬁed. Besides, researches, Signiﬁcant genetic risk com-
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rights reserved.on CAD that combine GWAS with metabolites are still limited. All pub-
lished GWA studies focused mainly on the discovery of novel genes,
while researchers paid little attention to the identiﬁcation of disease-
relatedmetabolites in part for lack of robust frameworks (e.g., metabol-
ic network) that consist of detailed intracellular relationships between
genes and metabolites. As one of the most authoritative human meta-
bolic network, the Edinburgh Human Metabolic Network (EHMN) has
been widely used in complex diseases [10–12]. Aleksej and Zelezniak
et al. used gene expression proﬁles and proposed a computational
method to identify Type 2 Diabetes related bio-markers in EHMN [13].
This network contains comprehensive cascade connections of enzymes,
genes, reactions and metabolites, which gives us an opportunity to
study CAD pathogenesis from the viewpoints of genetic factors and
metabolic network context.
In this paper, we proposed a genetic-based computational approach
named risk compounds mining (RCM) to identify signiﬁcant genetic
risk compounds (SGRCs) of CAD by appropriately quantifying high-
throughput SNP datasets and biologic network context and fusing
them. Due to genetic differentiation between organelles, our approach
was applied to the identiﬁcation of organelle-speciﬁc SGRCs in eight
sub-cellular networks (cytoplasm (C), extracellular space (E), mito-
chondria (M), Golgi apparatus (G), endoplasmic reticulum (R), lyso-
some (L), peroxisome (X) and nucleus (N)), respectively. After ﬁnding
CAD genetic risk compounds, we adopted CAD related genes to validate
the feasibility and efﬁciency of our approach. Besides, by literature
search, many SGRCs in our study were conﬁrmed to be traditional risk
factors of CAD. Furthermore, we integrated three widely accepted
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of our SGRCs. These results provided the evidence that the high herita-
bilities of SGRCs in our study play an important role in pathogenesis of
CAD and the newly discovered metabolites could possibly serve as
bio-markers for CAD clinical diagnosis in future researches.
2. Results
2.1. The distribution of CAD related SGRCs
In this paper, we proposed the RCM method (Materials and
methods) to screen CAD genetic risk related metabolites in EHMN.
However, in different organelles, the same metabolic reaction may be
catalyzed by different enzymes [21], which suggests that each com-
pound might have different genetic risk values in different organelles.
The scoring method in our study was based on the fact that enzymes
as biological catalysts of metabolic reactions have high speciﬁcity [22].
As a result, we utilized CAD high-throughput SNP datasets and EHMN
to screen SGRCs in eight sub-networks, respectively. Totally, 209
SGRCs have been screened out (additional ﬁles Table S1); we found
most SGRCs concentrated on three organelles: mitochondria, endoplas-
mic reticulum and peroxisome (Fig. 1A). Mitochondria, as the leading
factor of coronary artery disease [23], include 39 SGRCs (19%); there
are 60 SGRCs (29%) presented in the endoplasmic reticulum, which is
coincident with the fact that the endoplasmic reticulum stress is the
main reason for atherosclerosis [24]; 48 SGRCs (23%) were located in
the peroxisome and this organelle is associated with the prevalence of
CAD inﬂammation [25]. Besides, according to the KEGG classiﬁcation
standard [26], all SGRCs were participated in 74% of the human meta-
bolic pathways (additional ﬁles Table S5) and encountered in ﬁve
basic metabolic processes (Fig. 1B). Lipid metabolism contains the
most SGRCs (42%), followed by amino acid metabolism (26%), VitaminFig. 1. The distribution of CAD SGRCs identiﬁed by RCM method. (A) The pie chart
showed the distributions of SGRCs among eight sub-cellular networks. (B) The pie
chart showed the distribution of SGRCs among ﬁve basic metabolic categories.and Cotactor metabolism (13%), Carbohydrate metabolism (13%) and
Nucleotide metabolism (6%). As described above, most of the SGRCs
seemed to be present in different organelles, indicating that SGRCs
have their speciﬁc genetic risks in different cellular organs.
2.2. The hereditary of CAD genes and metabolites
However, besides metabolites, the heritability of CAD related genes
is another important factor which can't be ignored in the research of
CAD genetics [27]. Having obtained these SGRCs, we sought to further
analyze the genetic risk of CAD. CAD related genes have been discovered
in recent studies comprehensively [16], and we considered combining
themwith SGRCs in the analysis of CAD's genetic risk. First, we were in-
terested in the issue ofwhether these disease genes of CAD have genetic
risks through our method. We totally obtained 318 CAD related genes
from the CAD gene database [16], and there are 82 CAD related genes
present in EHMN (additional ﬁles Table S4). With the RCM method
(Materials and methods) used here, we found the risk value of CAD re-
lated genes is generally higher than the background (5.304/3.221;
Wilcoxon test; Pb0.05). As expected, the results were consistent with
previous studies that CAD related genes are heritable [28]. Interestingly,
32 metabolic compounds (additional ﬁles Table S2) regulated by CAD
related genes have been found to be SGRCs, and their average risk
value is generally higher than that of all the SGRCs (Wilcoxon test,
Pb0.05). Furthermore, through functional enrichment analysis, 32
SGRCs are mainly concentrated in lipid and lipoprotein metabolism,
glucosemetabolism, homocysteinemetabolism, integrity of endothelial
cells, abnormal vascular smooth muscle cells, and oxidation–reduction
(additional ﬁles Table S2). The results above showed that part of CAD
related genes are closely correlated with the risk factors in CAD, and
the SGRCs which are directly regulated by those genes can possibly
serve as hereditary factors in the progress of CAD.
2.3. Literature retrieval and functional classiﬁcation of SGRCs
We adopted literature retrieval to look for the evidence of the corre-
lation between SGRCs and CAD pathogenesis. To all 209 SGRCs, 103
SGRCs (49.3%) had been reported in the literature (additional ﬁles
Table S7). For instance, Acylglycerol (risk value (RV)=269.4390, P=
7.24E−07, C), Diacylglycerol (RV=269.43900, P=7.24E−07, C) and
Glycerol lipid (RV=68.5722, P=2.55E−11, C) are themost commonly
used indicators in CAD clinical detection [29]. Elevated levels of Triglyc-
eride (RV=269.4390, P=7.24E−07, C) in blood is often accompanied
by coagulation dysfunction and abnormal lipid metabolism, which are
important factors in vascular damages [30]. An increase of the
NADH+(RV=4.2915, P=1.68E−07, M)/NADPH (RV=4.2915, P=
2.05E−09, M) level would accelerate oxygen metabolism, leading to
endothelial dysfunction, inﬂammation and extracellular matrix deposi-
tion, and eventually accelerate the vascular atherosclerosis progress
[31–33]. High levels of lipoprotein which transports cholesterol in the
blood are thought to be associated with increased risk of CAD and ath-
erosclerosis [1], while the low-density lipoprotein can effectively re-
duce the incidence of CAD [34]. Diacylglycerol (DAG) (RV=269.4390,
P=7.24E−07, C) could potentially affect lipid sensitivity via activation
of serine/threonline kinases or alterations in phospholipid membrane
composition, both ofwhich could lead to lipid synthesis [35]. All togeth-
er, identiﬁcation of these SGRCs known to be involved in coronary ar-
tery disease pathogenesis provided further evidence for the validation
of our approach.
Nevertheless, there have been no comprehensive classiﬁcations
for function categories of metabolites and their roles in CAD. There-
fore, we considered to build a resource of our SGRCs mapping with
CAD related functional categories for better understanding the role
of genetic risk factors in the CAD pathogenesis. Here, we used three
widely accepted databases as data sources of functional categories,
including Pubchem [36], MBRole [20] and KEGG [26]. By integrating
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genic mechanism of CAD into 12 categories (Table 1). Furthermore,
we also classiﬁed literature conﬁrmed SGRCs into 12 categories. Inter-
estingly, nearly half of SGRCs (45.6%) were classiﬁed into the catego-
ries of lipid and lipoprotein metabolism and oxidation–reductionTable 1
The CAD pathogenic mechanisms of SGRCs in eight sub-networks.
aFunctional categories KEGG ID cCellular
localization
Lipid and lipoprotein
metabolism
C00116 C01885 C00641 C00422 C00165
C11136 C02112
C
Purine alkaloids C00655 C
Oxidation–reduction C03150 C00162 C00060 C
bOthers CE2884 CE6272 C11061 C00330 C00362 C
Lipid and lipoprotein
metabolism
C00116 C00422 C00641 C01885 C00165 E
Immune and
inﬂammation
C00060 C000162 E
Oxidation–reduction C00162 C00060 E
Purine alkaloids C00153 E
Thrombosis C00035 C00325 G
Lipid and lipoprotein
metabolism
G00063 G00081 G
Glucose metabolism C00325 C01019 C00270 G
bOthers C04936 C04922 G
Lipid and lipoprotein
metabolism
C02686 C00249 C00319 C12144 L
bOthers C02472 C06128 C00069 C06412 L
Renin–angiotensin
system
C00020 C05993 C01344 M
Homocysteine
metabolism
C00082 C00025 C05938 C00179 C01165
C03921 C01157 C03287 C00134
M
Immune and
inﬂammation
C00134 M
Vascular smooth
muscle cell
abnormalities
C00410 C00025 C00535 C04295 CE0926
C03912
M
Lipid and lipoprotein
metabolism
C00416 C00164 C00681 M
bOthers C00042 C00332 C02839 C00356 C00004
C00003 C00787 C01653 C00040 C09820
C00080 C00086 C01645
M
Endothelial integrity C00021 N
Lipid and lipoprotein
metabolism
C00399 N
bOthers C00080 C05544 C05545 C05546 C00019
C02415
N
Oxidation–reduction C00390 C00399 N
Endothelial integrity C14786 C14852 C06790 C11088 C13645
C14857 C14859 C14870 C00051
R
Lipid and lipoprotein
metabolism
C05957 C04685 R
Renin–angiotensin
system
CE5244 R
Oxidation–reduction C14786 C14852 C06790 C11088 C13645
C14857 C14859 C14870 CE6235 C11304
C02320
R
bOthers C05953 R
Gender difference C14786 C14852 C06790 C11088 C13645
C14857 C14859 C14870
R
Lipid and lipoprotein
metabolism
C00040 X
Immune and
inﬂammation
C09819 X
Oxidation–reduction C00080 C00003 C00004 C09820 X
a Functional categories: lipid and lipoprotein metabolism, glucose metabolism, renin–
angiotensin system, endothelial integrity, gender difference, vascular smooth muscle cell
abnormalities, homocysteine metabolism, immune and inﬂammation, Purine alkaloids,
thrombosis, oxidation–reduction and others.
b Others including generic compound participate in multiple metabolic reactions,
nucleic acids, peptides and common amino acids.
c Cellular localization: C= cytoplasm, E= extracellular space, M=mitochondria, G=
Golgi apparatus, R = endoplasmic reticulum, L = lysosome, X = peroxisome and N =
nucleus.(Table 1). Current studies indicated the leading cause of cardiovascular
disease is lipid metabolism disorder [37,38]. Homocysteine (RV=
15.4722, P=0.0015, N) and Trichloroethene (RV=45.6722, P=
0.0201, R) are related to endothelial dysfunction [39,40], therefore we
classiﬁed them into endothelial integrity category. Moreover, some
plasminogen activator inhibitor like GDP (RV=14.3203, P=3.24E−
13, G) and GDP-L-fucose (RV=14.7214, P=4.75E−08, G) are essential
to thrombosis [41]. As is shown in Table 2, the rest of SGRCs are specif-
ically distributed in other CAD functional categories, such as glucose
metabolism, renin–angiotensin system, gender difference, vascular
smooth muscle cell abnormalities, homocysteine metabolism, immune
and inﬂammation and Purine alkaloids. The above results have clearly
classiﬁed part of the SGRCs into 12 CAD functional categories, which
suggested that some of our SGRCs have essential roles in the mecha-
nisms of the CAD pathogenesis. In this work, there were also some
SGRCswhich have not been conﬁrmed by current studies. Interestingly,
many of these non-literature conﬁrmed SGRCs belong to lipid metabo-
lism and glucose metabolism. A prime example is that Isopentenyl di-
phosphate (RV=9.2088, P=0.0472, X), 3-Oxododecanoyl-CoA (RV=
8.0135, P=0.0381, X) and (S)-Hydroxydecanoyl-CoA (RV=9.4308,
P=0.0347, X) are core metabolites in lipid metabolism an essential
metabolic process of CAD pathogenesis [42], which suggests that
these newly discovered SGRCs are likely to be prime candidate bio-
markers of CAD risks.
2.4. Comparison between the RCM method and traditional approach
Wecarried out traditional approach to screen traditional genetic risk
compounds (TGRCs) of CAD from the overall metabolic background. As
a result, 89 TGRCs have been screened out (additional ﬁles Table S6),
and 84(94%) of TGRCs were included in our SGRCs. Besides, 125 of
SGRCs derived from RCMmethod were not identiﬁed by the traditional
method (Fig. 2A). According to the distribution of TGRCs in organelles,
most of TGRCs are predominantly in themitochondria and endoplasmic
reticulum, which is consistent with the results of the RCMmethod. We
next compared the frequency of intra-organelle distributions of genetic
risk compounds between the overlaps and differences. Interestingly,
the overlaps were more likely to localize in single organelles (Fig. 3).
However, the rest of SGRCs ﬁltered out by traditional method were dis-
covered to localize among multi-organelles (Fig. 3). These differences
were largely due to the fact that although traditional method could ex-
tract metabolic reactions from the overall metabolic background, those
reactions occurring in multi-organelles were then regarded as one
whole entity during the identiﬁcation process of genetic risk com-
pounds. Thismight lead to the lack of identiﬁcation of those compounds
located in multi-organelles. On the contrary, the RCM method took
sub-cellular localizations into account by separating EHMN into eight
sub-networks and made the identiﬁcation of potential organelle-
speciﬁc SGRCs more reasonable and accurate.
In addition, literature retrievalswere carried out to search for the ev-
idence of disease relatedness of genetic risk compounds screened out by
traditional and our methods. As a result, nearly one third of TGRCs (30)
were found to be associated with CAD pathogenesis, all of which were
also encountered in SGRCs. It should be noted that majority of all veri-
ﬁed CAD-risk metabolites (73) found by our method were neglected
by traditional method. To be more exact, the overlapping risk metabo-
lites participated in several CAD-related functional categories includingTable 2
Frequency of cases and controls for each of two alleles at a SNP locus.
Allele X Y
Case a b
Control c d
aa–d represents the frequency of the speciﬁc allele X or Y, respectively.
Fig. 2. Comparisons between the overlaps and differences of the two approaches. (A) Venn diagram for overlap metabolites identiﬁed by RCM and traditional method. (B) A
heatmap of metabolits' functional distribution for literature-conﬁrmed 30 metabolites both in RCM and traditional method. (C) A heatmap of metabolites' functional distribution
for literature-conﬁrmed 73 metabolites only identiﬁed by RCM. Black indicates high levels of functional enrichment, and gray indicates low levels.
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ty and gender difference (Fig. 2B). Noticeably, the literature conﬁrmed
that SGRCs identiﬁed only by the RCMmethodwere also found to be re-
lated to other pathogenic processes of CAD (e.g., renin–angiotensin
system, vascular, smooth,muscle cell abnormalities and homocysteine me-
tabolism) (Fig. 2C), suggesting that the traditional method experienced
lower power/performance in identifying genetic risk metabolites in the
pathogenic processes of CAD.3. Discussion
Coronary artery disease is considered to be caused by multiple ge-
netic and environmental factors. In this paper, we proposed the RCM
method which considered both the genetic factors and biologic net-
works to ﬁnd CAD-related SGRCs. It should be noted that we did not
extract all the reactions from metabolic networks as traditional
methods, but introduced a more reasonable method by separating
EHMN into eight sub-networks and dealt with those networks, re-
spectively. Interestingly, we found 209 SGRCs distributed speciﬁcally
among the 8 sub-networks, and most SGRCs concentrated on theFig. 3. A comparison of intra-organelle frequencies between overlaps and differences.mitochondria (19%), endoplasmic (29%) and peroxisome (23%). Un-
fortunately, current studies on sub‐cellular localization of classes of
metabolites (and enzymes) appeared to be incomprehensive. It still
requires a lot of observations and experiments to accommodate met-
abolic localization resources. We will continue to focus on the devel-
opment of this ﬁeld in order to better decipher our results.
Through literature retrieval and functional classiﬁcation, majority of
SGRCs associated with coronary artery disease have been well veriﬁed.
Furthermore, some SGRCs termed as conventional genetic risk factors
are closely related to the pathogenesis of coronary artery disease. In ad-
dition,many SGRCswith higher heritabilities than conventional genetic
risk factors suggested a strong correlation between genotype and phe-
notype. Comparing with traditional approach, the RCM method not
only identiﬁed organelle-speciﬁc risk compoundsmore comprehensive
and accurate, but also provided additional insights into the pathogene-
sis of CAD in the perspective of sub-cellular localization. These results
have strongly illustrated that CAD-related SGRCs using the RCMmethod
are reliable, which might provide more clues for traditional clinical di-
agnosis. However, some of the newly discovered SGRCs have not been
conﬁrmed yet, further experimental studies are necessary to assess
the underlying mechanisms of these SGRCs in CAD.
As we know, CAD is likely to be caused by a series of factors, for ex-
ample, geneticmutations, similar environment among familymembers,
or the interaction between environmental factors and the traditional
genetic factors [43]. At present, researches on the integration of genetic
andmetabolic networks are still limited. However, the results of our re-
search not only found genetic risk relatedmetabolites conﬁrmedwell in
CAD, but also introduced a comprehensive list of functional categories
of our SGRCs, which provided novel insights into CAD pathophysiology
and genetics.
4. Materials and methods
4.1. Data source
The network was derived from the Edinburgh Human Metabolic
Network, EHMN [14], which was reconstructed by integrating genome
annotation information from different databases and metabolic reac-
tion information from literature. EHMN contains nearly 3000metabolic
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according to their functional relationships. In our study, the network
was separated into 8 sub-networks (additional ﬁles Table S3) according
to its localization information, including cytoplasm, extracellular space,
mitochondria, Golgi apparatus, endoplasmic reticulum, lysosome, per-
oxisome and nucleus.
Genotype frequencies of tested SNPs of case–control samples were
downloaded from the Welcome Trust Case Control Consortium
(WTCCC) online system from the following samples using the 500K
Affymetrix chip: 459,448 samples of CAD [15]. Location information
of the human genes was acquired from the NCBI genome database
(Build 37.1, Feb 2009). CAD related genes were downloaded from
the CADgene database [16]. Human Metabolic pathway information
was obtained from the KEGG database [17].
4.2. SNP signiﬁcance analysis and risk evaluation
In this study, we used high‐throughput SNP dataset as research
source. Then we adopted a t-test and minimal allele frequency meth-
od to screen the frequency of cases and controls (Table 2).
By using the matrix table above, we calculated the statisticsχ2and
computed the corresponding probability p value of each SNP. Under
the signiﬁcance level of 0.05, a SNP set was preliminarily screened
for the following study. The Pearson χ2 formula was as follows:
χ2 ¼ ad−bcð Þ
2 aþ bþ cþ dð Þ
aþ bð Þ bþ dð Þ dþ cð Þ cþ að Þ ð1Þ
An Srisk statistic can be acquired for each SNP if its signiﬁcance
level meets the threshold of 0.05 [18].
Srisk ¼
log
f case Xð Þ
f control Xð Þ
f case Xð Þ > f control Xð Þ > 0&&Pb0:05
log
f case Yð Þ
f control Yð Þ
f case Yð Þ > f control Yð Þ > 0&&Pb0:05
0 others
8>><
>>:
ð2Þ
Here fcontrol(X), fcontrol(Y), fcase(X),fcase(Y) are the frequencies of
cases and controls at the alleles X and Y, respectively. However, if
the P value of a SNP was not signiﬁcant, its risk value was set to be
0. For each SNP, theSrisk value was introduced to depict its relation-
ship with CAD. The Sriskvalue could, in some sense, reﬂect the genetic
effects of CAD.
4.3. Evaluation of gene risk
Most of functional elements (enhancers, repressors) are b500 kb
away from genes; and most linkage disequilibrium blocks are less
than 500 kb as well [19]. Therefore, for each gene termed as g, we
choose the highest risk value among the SNPs which located within
g as its genetic score. The formula was as follows:
risk gð Þ ¼ max
1≤x≤m
Srisk1 ; Srisk2 ; ::; Sriskx ; ::; Sriskm
n o
ð3Þ
where m is the total number of SNPs mapped to g, Sriskx is the risk
value of the x-th SNP located in g.
4.4. Evaluation of reaction risk
Generally, the genotype of complex diseases is considered to be
related with genetics and surrounding factors. Herewith, we calculat-
ed the average risk value of the gene gi which was mapped into the
reaction Rt.
Rt : Aþ B→
g1 ;g2 ; ::::;gi; ::::gn
C þ D ð4ÞFor each Rt, we have deﬁned its risk value as follows:
SRt ¼
1
n
Xn
i¼1
risk gið Þf g ð5Þ
Here, A, B, C and D represent the products and substrates of a given
reaction; gi(i=1,2,⋯,n) represents a regulation gene of a metabolic re-
action; n is the total number of genes in Rt and risk(gi) is the risk value
of the i-th gene in the reaction.
4.5. Evaluation of compound risk
Here we adopted an average risk effect to measure the genetic
risks of metabolic compounds. For each compound, we evaluated
the risk scoring of Scompound with relative value by calculating the av-
erage risk value of Sreactionk which the compound participated in, and
its formula was:
Scompound ¼
XL
k¼1
Sreactionk
n o
L
ð6Þ
In formula (6), L is the total number of reactions which the com-
pound participated in.
4.6. Randomization test
In order to detect the signiﬁcance of genetic risk compounds, we
promoted 1000 times randomization to all sub-cellular networks, re-
spectively. The randomization test was carried out for each compound;
it was introduced to estimate the stability of the RCM method. This
approach retained the structure of the metabolic sub-networks and
randomized only the frequency of all the compounds. We adopted
Z-score to screen the statistically signiﬁcant risk compounds (Z>3.14;
Pb0.05).
Z ¼ Scompoundj−μcompoundj
σcompoundj
ð7Þ
In formula (7), Scompoundj represents the real risk value of the j-th
compound, μcompoundj is the mean risk value of the j-th compound for
1000 randomization and σcompoundj is the standard deviation of 1000
times randomization for each compound. The calculated p values from
Z-scores were deﬁned as measures of risk levels. In the next step, we
screened SGRCs by the RCMmethod from 8 sub-networkswith P values
under a signiﬁcant threshold of 0.05.
4.7. Algorithm of RCM method
The steps of the RCM method are shown as follows (Fig. 4):
I) Calculate risk values for all the SNPs whose P values meet the
threshold of 0.05 according to the Pearson χ2 statistic.
II) Screen and map SNPs to the corresponding genes in the EHMN.
i) Map all the SNPs in step I to the corresponding gene that are
located b500 kb away from g.
ii) Select the maximum risk value Sriskx as the genetic statistic
value for risk(g)
III) Compute theSRt for the reaction Rt as formula (5)
IV) Compute the Scompound for the compound as formula (6)
V) Repeat steps III and IV to compute Scompound values for all the
compounds in the network.
VI) Construct random networks for 1000 times, repeat steps III and
IV to compute all the Scompound values in random networks.
VII) Compute Z‐scores of allmetabolites in thenetwork as formula (7),
Fig. 4. Algorithm of the RCM method.
287X. Li et al. / Genomics 100 (2012) 282–288and the screened SGRCswith Z‐scores above the threshold of 3.14
(Pb0.05).
4.8. Functional enrichment analysis
Metabolite function enrichment in our study was calculated by the
MBRole online system [20].
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